title: Secondary neurolymphomatosis detected by whole-body diffusion-weighted magnetic resonance imaging: a case report.
abstract: Neurolymphomatosis (NL) is a rare clinical entity defined as peripheral nervous system infiltration by lymphoma. The diagnosis is difficult and often elusive. Whole-body diffusion-weighted magnetic resonance imaging (DW MRI) was developed to enhance the detection of vaguely delineated tumors. Here, we describe the case of a 71-year-old male with secondary NL of diffuse large B-cell lymphoma (DLBCL) that was successfully detected by whole-body DW MRI. The patient was diagnosed with DLBCL extending from the ethmoidal sinus to the nasal cavity, orbital cavity, and anterior cranial fossa. Although he was administered R-THP-COP chemotherapy and the tumor remarkably decreased in size, he developed painful paresthesia and weakness in the left upper and bilateral lower extremities during treatment. Because lymphoma cells were detected in his spinal fluid, high-dose methotrexate (MTX) and weekly intrathecal MTX and cytarabine injections were administered. Test results for lymphoma cells in the spinal fluid became negative ; however, the neurological disorders progressed. Whole-body DW MRI was performed as whole-body screening and could localize NL at the left cervical and bilateral lumbar nerve roots. Both cervical spine plain MRI and enhanced computed tomography performed around the same time could not detect the cervical lesion. Our case report suggests that whole-body DW MRI is a useful diagnostic imaging procedure, especially as whole-body screening in facilities where PET/CT is not available.
authors.affiliation: Department of Hematology, Oami Municipal Hospital.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshino
authors.forename: Emiko
authors.initials: E
authors.lastname: Sakaida
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Takeda
authors.forename: Chika
authors.initials: C
authors.lastname: Kawajiri
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takagi
authors.forename: Chiaki
authors.initials: C
authors.lastname: Nakaseko
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D038524:Diffusion Magnetic Resonance Imaging; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005005:Ethmoid Sinus / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000188:drug therapy; D010255:Paranasal Sinus Neoplasms / Q000175:diagnosis; D010524:Peripheral Nervous System Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D016658:Psoas Muscles / Q000473:pathology; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone